Thoughts on the selection of antimicrobials for current pertussis treatment in China
10.3760/cma.j.cn101070-20231128-00385
- VernacularTitle:国内当前百日咳治疗的抗菌药物选择之我见
- Author:
Kaihu YAO
1
;
Qinghong MENG
;
Wei SHI
;
Lin YUAN
;
Yahong HU
Author Information
1. 国家儿童医学中心，首都医科大学附属北京儿童医院，北京市儿科研究所感染与微生物研究室，儿科学国家重点学科，儿科重大疾病研究教育部重点实验室，国家呼吸系统疾病临床医学研究中心，北京 100045
- Keywords:
Pertussis;
Bordetella pertussis;
Drug resistance;
Antimicrobials;
Treatment
- From:
Chinese Journal of Applied Clinical Pediatrics
2024;39(2):85-88
- CountryChina
- Language:Chinese
-
Abstract:
For a long time, macrolides have been the first choice for the antibacterial treatment for pertussis.However, in the past decade, resistance to macrolide antimicrobials has been common in clinically isolated Bordetella pertussis in China, which is in contradiction with the recommended macrolide treatment.Therefore, Trimethoprim-Sulfamethoxazole (TMP-SMZ) is suggested as the first choice for antibacterial treatment for pertussis in China, with a dosage determined according to age and body weight, lasting 14 days.If TMP-SMZ cannot be used, full-dose and full-course β-lactam antimicrobials may be used, of which the effects should be assessed carefully.The impact of other antibacterial drugs, such as quinolones and tetracyclines, on the elimination of Bordetella pertussis should also be evaluated as soon as possible to treat adult pertussis and potential cases caused by drug-resistant bacteria in future.
